Search
tesamorelin (Egrifta)
Indications:
- treatment of lipodystrophy in HIV-Infected patients
- can reduce accumulation of abdominal fat but does not treat hyperlipdemia or insulin resistance
Dosage:
- once a day injection
Adverse effects:
- arthralgia
- abdominal pain
- swelling
- myalgia
- erythema & pruritus at the injection site
- worsening of glycemic control
Mechanism of action:
- growth hormone-releasing factor
General
endocrine agent
Database Correlations
PUBCHEM correlations
References
- Physician' First Watch, Nov. 12, 2010
Massachusetts Medical Society
http://www.jwatch.org
- FDA NEWS RELEASE, Nov. 10, 2010
FDA approves Egrifta to treat Lipodystrophy in HIV patients
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm233516.htm
- NEJM Knowledge+